177 results about "Salivary Gland Proteins" patented technology

The invention discloses a method for producing transgenic mice through a homologous recombination technology. The method comprises the following steps: replacing mouse NGF genes on mouse chromosomes by human NGF genes through a Cas-9/CRISPR gene knock-in technology, and obtaining the genes with homozygous human NGF genes through breeding and knocking the genes in mice, thus obtaining filial generation mice with salivary glands capable of secreting human NGF. Compared with the conventional targeting technology utilizing positive and negative double screening homologous recombination genes, the method disclosed by the invention is simple to operate, capable of being realized only by transfecting mouse embryonic stem cells by three plasmid DNAs or carrying out pronucleus injection on the zygotes of mice, and high in success rate which is up to 2-5% and remarkably higher than the mouse embryonic stem cell positive rate of 0.1% of the common gene targeting technology.

Disclosed herein are pharmaceutical compositions comprising various combinations of an antimuscarinic or an anticholinergic agent, a compound that causes stimulation of salivary glands, and a compound that relieves constipation. Also disclosed are methods of treating a patient suffering from overactive bladder comprising administering to the patient the above pharmaceutical composition.

The invention relates to fusion protein used to prevent and cure I type and II type diabetes and its preparation method and application. It supplies the fusion protein which is formed by glucagon analogy peptide GLP-1, GLP-1 mutant and IgG-Fc, its analogy factor lizard salivary gland polypeptide extendin-4 and IgG-Fc, and the application of the above fusion protein and its DNA used in diabetes prevention and therapy. The fusion protein can increase not only GLP-1 effect, but also the affinity and immunological tolerance of ligand, which is excreted with the form of homogeneity dimmer to improve polypeptide drug effect, overcomes the defect of the GLP-1 for short half-life, and simplifies purification process.

The invention relates to a method for treating, controlling, or preventing cancerous cell phenotypes and growths in an animal involving the administration of gaseous nitric oxide to one or administration sites in a body. The invention generally is capable of treating cancers found in or on the adrenal gland, bladder, bones, brain, breast, cervix, colon, colorectum, esophagus, gastrointestinal tract, heart, kidney, liver, large intestine, lungs, mouth, ovaries, pancreas, parathyroid, pituitary gland, prostate, salivary gland, skin, small intestine, spleen, stomach, thymus, thyroid, testicles, urinary tract, uterus, vagina, and so forth.

Medical devices, methods and kits useful in the disruption and removal of unwanted materials, such as calculi and other formations, from within body lumens are described. The disclosure describes particular embodiments and methods useful in the lithotriptic removal of stones from the salivary glands.

The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.

A polymeric stent, especially useful in surgical endoscopy and for the treatment of salivary gland ducts comprising; an elongated tube (1), wherein the proximal end (3) of said tube is having a funnel-like shape; and wherein said funnel further comprise at least one gorge (5a), which enables the suturing of said stent to said duct. The invention also relates to a method for implanting the polymeric stent into the lumen of a salivary gland duct.

A system, a device and a method for electrically detecting a lack of saliva in an oral cavity of an individual and for electrically stimulating the oral cavity so as to induce production of saliva from at least one salivary gland are disclosed. The system includes a control device for detecting a measure of salivation in the individual and for delivering electrical impulses to the oral cavity of the individual, a check device for checking a state of the control device and for modifying at least one parameter of the control device, and, a computer device for exchanging information with the check device.

The invention discloses a device for simulating digestion in oral cavities and a method for applying the device. The device comprises components including a saliva dish, a constant-flow pump, a water bath kettle, a grinder, a stirrer, a reactor, an electric controller and the like. The method includes regulating the temperature of the water bath kettle until the temperature of the water bath kettle reaches 37 DEG C, adding saliva into the saliva dish, adding solution or dispersion liquid of to-be-tested substances into the reactor, starting the constant-flow pump and adding the saliva into the reactor; enabling the grinder and the stirrer to simulate chewing actions of teeth and stirring actions of tongues; continuously adding the saliva into the reactor via a hose to simulate a secretion effect of salivary glands; replacing water in the water bath kettle by boiling water to remove activity of salivary amylases after the secretion effect of the salivary glands is simulated for 30-40 minutes, repeatedly carrying out a digestion simulation procedure by three times, and detecting digestion conditions of the to-be-tested substances by a liquid-phase process. The device and the method have the advantages that specific digestion simulated in the oral cavities is described in detail for the first time, structures of various portions of the oral cavities and corresponding functions of the structures of the various portions of the oral cavities are simulated, accordingly, first-step digestion conditions of various active or nutrient substances can be observed after the various active or nutrient substances are fed into human bodies, and the device and the method can assist in exploring digestion conditions of the various active or nutrient substances after the various active or nutrient substances are fed into the human bodies.

A method for mass spectrometric analysis of a saliva sample possibly containing mycophenolic acid or its metabolites mycophenolic acid phenyl glucuronide (MPAG) or mycophenolic acid acyl-glucuronide (Acyl-MPAG), including the steps: (a) providing a saliva sample containing one or more drug or metabolites; (b) deproteinating the sample; (c) separating the one or more drug or metabolites from the saliva sample; and (d) analyzing the one or more drug or metabolites using a mass spectrometer. The sample containing one or more MPA or metabolites is obtained from in an oral fluid based biological samples i.e. whole saliva or saliva obtained by chemical or mechanical stimulation or from specific salivary glands. The size of the sample contains one or more MPA or metabolites is at least about 100 microL. A kit for use in mass spectrometric analysis of a sample may contain one or more MPA or metabolites from saliva samples, comprising: (a) reagents for deproteinating of the saliva sample, including internal standards; (b) reagents for separating the one or more MPA or metabolites from the saliva sample; (c) reagents for analyzing the one or MPA or metabolites using a mass spectrometer; (d) a solution of one or more MPA or metabolites in saliva samples; and (e) instructions for analyzing the one or more MPA or saliva using a mass spectrometer. The kit includes (a) mobile phase solutions; (b) a chromatography column; and (c) a quality control specimen.

Nanobacteria contribute to pathological calcification in the human and animal body, including diseases such as kidney stones, salivary gland stones, dental pulp stones and atherosclerosis. The present invention provides methods for sterilizing articles contaminated with nanobacteria. The present invention also provides methods of treating patients infected with nanobacteria. In particular, the present invention provides a method for preventing the recurrence of kidney stones in a patient that has suffered from kidney stones, comprising administration of an antibiotic, a bisphosphonate, or a calcium chelator, either alone or in combination, in an amount effective to inhibit or prevent the growth and development of nanobacteria.

The invention discloses a modeling method of an Sjogren syndrome mouse model. The modeling method comprises the following steps: killing mice, taking out bilateral salivary glands and peeling off capsules and connective tissues; washing with PBS (Poly Butylenes Succinate); adding the PBS according to the amount of adding 0.5ml of the PBS into each salivary gland; shearing the salivary glands into pieces, and uniformly homogenizing and centrifuging in an ice bath; then taking supernatant and quantifying salivary gland antigens by adopting a BCA (Bicinchoninic Acid) protein quantifying method; adjusting the concentration of the salivary gland antigens to be 4mg/ml by utilizing the PBS; adding equal quantity of an FCA (Freund Complete Adjuvant) or an FIA (Freund Incomplete Adjuvant) and diluting the concentration to be 2mg/ml; repeatedly blowing and beating until two liquid phases are dissolved mutually to form an ivory color; randomly grouping C57BL/6 mice and shaving off furs on the backs of the mice; carrying out intradermal multi-site injection of 2mg/ml mouse salivary gland antigens prepared by the FCA on the back and tails of the mice on the current day and the 7th day, wherein the injection amount is 0.1ml per mouse; injecting equal quantity of the salivary gland antigens prepared by the FIA on the 14th day through the same method; after modeling for about 6 weeks, detecting indexes and screening the successfully modeled mice. The modeling method disclosed by the invention is high in modeling efficiency and short in modeling time.

Described herein is the finding that patients with Sjögren's syndrome exhibit a statistically significant increase in expression of BMP6 in the salivary gland, relative to healthy control subjects. Also described herein is the finding that overexpression of BMP6 in the salivary glands of mice results in an increase in electrical potential across the salivary gland. Thus, provided herein are methods of diagnosing a subject as having Sjögren's syndrome, or at risk for developing Sjögren's syndrome, by measuring the level of BMP6 expression in a salivary gland of a subject, measuring electrical potential in a salivary gland of a subject, or both. Also provided herein are methods of treating a subject with Sjögren's syndrome by administering an agent that inhibits expression of BMP6 expression or activity. Also described herein is the use of XIST and MECP2 as diagnostic and therapeutic targets for male Sjögren's syndrome patients.

A pharmaceutical composition using natural gonadotropin-releasing hormone (GnRH), and/or some of its mimetic peptides, indistinctly bound by its amino or carboxyl extremes to a carrier molecule; in one case by its carboxyl extreme and in the other case by the amino terminal extreme, thus eliciting a faster and more potent immunological response against the endogenous GnRH hormone. This finally leads to the ablation of the GnRH and consequently of the rest of the involved hormones in the stream GnRH/LH-FSH/Testosterone-(estrogens). An advantage of this formulation consists on facilitating the exposition to the immune system of a greater number of epitopes of the GnRH or its mimetics, minimizing thus the steric hindrance produced by the carriers. This invention has a direct application in the castration of pets and animals of economic interest, in the control of human fertility as well as in the treatment of hormone-sensitive tumors, such as that of the prostate, the breast, ovary, the endometry, testicles, hypophysis, salivary glands and other kinds of human tumors.

A method, composition and system for controlling termites wherein single carbohydrate-based compounds are used as both cellulase inhibitors and feeding stimulants. Di-saccharides, cellobioimidazole (CBI), fluoro-methyl cellobiose (FMCB), and mono-saccharides, fluoro-methyl glucose (FMG) and analogs thereof inhibit termite cellulose digestion, which leads to starvation or stimulates termite feeding to cause mortality. CBI, FMCB and FMG were tested against enzyme fractions that represented endogenous (foregut/salivary gland/midgut) and symbiotic (hindgut) termite cellulases in vitro and in vivo. Feeding stimulation by di-saccharides results in greater cellulase inhibitor intake throughout midrange concentrations (1 mM-10 mM), which is associated with significant termite mortality. In contrast, the monosaccharide inhibitor, FMG did not stimulate feeding, but did inhibit feeding at concentrations above 1 mM, causing mortality. With modification to create longer β-glycosidic chain lengths, the cellulase inhibitors identified herein can also be targeted to endoglucanase activity for increased efficacy and use as novel termite control compositions.

The invention falls into the field of biotechnology, and relates to an apyrase encoding gene of Aedes albopictus, and preparation method and application of protein thereof. In the invention, RNA is extracted from the salivary gland of Aedes albopictus; the apyrase encoding gene of Aedes albopictus is obtained by PCR; and an apyrase expression vector pET19b-apyrase is constructed. After abundant expression, purification and further identification, it has been proved that, the recombinant apyrase of Aedes albopictus has equal immune activity as natural apyrase of Aedes albopictus, can cause immune response of human, and has inhibitory activity against platelet aggregation. The inventive apyrase of Aedes albopictus can be used in the diagnosis of anaphylactic diseases induced by Aedes albopictus, and also be used as antithrombotic for treating thrombus caused by platelet aggregation.

The invention relates to a salivary gland immunoregulation polypeptide of a dieu cleg and the related genes and the application, belonging to the biomedical field. The immunoregulation polypeptide is a linear polypeptide coded with the Chinese Tabanidae salivary gland immunoregulation polypeptide genes, the sequence of which is glycin- glycin- valine- serine- glycin- valine- serine- aspartic acid- phenylalanine- glutamate- praline- isoleucine- glutamate- valine- serine- glycin- glutamate- aspartic acid- tyrosine- aspartic acid- serine- aspartic acid- glutamate- alanine- aspartic acid- glutamate- aspartic acid- glycin- lysine- alanine. The immunoregulation polypeptide gene is composed of 362 Nucleotides, wherein, the coding mature code salivary gland immunoregulation polypeptide of the dieu cleg is the 115th to the 204th nucleotide. The dieu cleg salivary gland immunoregulation polypeptide is used for inhibiting a plurality of cytokines, which is characterized by simple structure, convenient artificial synthesis and strong antibacterial activity, etc.

The present invention relates to a traditional Chinese medicinal preparation (heat-clearing, blood-cooling and body fluid-promoting beverage) for relieving head or neck tumor radiation therapy side effect: mainly comprising stomatitis, neck skin reaction, hematology variation (mainly indicating leucocyte decreasing), pharynx and esophagus mucosa injury and salivary gland change and etc. It is composed of heat-clearing and antitoxic, blood-cooling and stasis-eliminating, qi-invigorating and body fluid-promoting, spleen and stomach conciliating traditional Chinese medicine, with monarch,minister,assistant and guide to process reasonable compatibility, its medicine constitution according to their weight ratio is: scutellaria ( fried with alcohol) 10 to 15 gram, honeysuckle 10 to 15 gram, forgythia fruit 10 to 15 gram, rehmanniae radix 13 to 18 gram, red sage root 10 to 15 percent, radix paeoniae rubrathe 10 to 15 gram, Chinese angelica 8 to 10 gram, ginseng 6 to 10 gram, Schisandra chinensis 5 to 8 gram, atractylodes rhizome 8 to 10 gram, raw glycyrrhiza 8 to 12 gram. By clinical experiment, effect is obvious. It has characteristics for reducing injury of radiation ray to around normal tissue, promoting around normal tissue repairing, relieving pain caused by radiotherapy side reaction, ensuring radiotherapy successful accomplishment.